What is Xilio Development Inc?
, a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 57.04M, and a P/E ratio of 12.4x.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.